 This study will evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis B CHB viral infection who have been virally suppressed with an oral antiviral medication. Participants will be randomized in a 1:2:2:2 ratio to the treatment arms for 20 weeks. 